IP Library Assignment 073559/0435
Patent Assignment
Reel/Frame 073559/0435

Assignment of Assignor's Interest

Recorded: 2026-01-23 Pages: 20
Assignor
AKAMIS BIO LIMITED
Executed: 2025-12-22
Assignee
AKAMIS BIO, INC.
245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MASSACHUSETTS, 02142
Covered Properties (35)
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 7,510,868 →
Application: 11/136,912 →
Publication: US US20050265973A1
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 8,158,599 →
Application: 12/413,748 →
Publication: US US20090227000A1
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 8,765,463 →
Application: 13/443,055 →
Publication: US US20130230902A2
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 9,115,337 →
Application: 13/798,784 →
Publication: US US20130209409A1
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 9,034,344 →
Application: 13/862,875 →
Publication: US US20130217095A1
Chimeric Adenoviruses for Use in Cancer Treatment
Patent: 9,234,185 →
Application: 14/464,086 →
Publication: US US20150037874A1
Chimeric adenoviruses for use in cancer treatment
Application: 60/574,851 →
A Dosing Regime and Formulations for Type B Adenovirus
Application: 14/896,294 →
Publication: US US20160120922A1
Dosing Regime and Formulations for Type B Adenoviruses
Application: 17/448,549 →
Publication: US US20220054563A1
Dosing Regime and Formulations for Type B Adenoviruses
Application: 19/237,875 →
Publication: US US20260216263A1
A Method of Making Adenovirus and Corresponding Plasmids
Application: 15/107,451 →
Publication: US US20160319304A1
Oncolytic Adenoviruses Armed with Heterologous Genes
Patent: 9,987,314 →
Application: 15/031,716 →
Publication: US US20160331793A1
Oncolytic Adenoviruses Armed with Heterologous Genes
Application: 15/967,093 →
Publication: US US20180311291A1
Oncolytic Adenoviruses Armed with Heterologous Genes
Application: 17/247,787 →
Publication: US US20210187047A1
Oncolytic Adenoviruses Armed with Heterologous Genes
Application: 18/583,342 →
Publication: US US20240325472A1
Group B Adenovirus Modified in the E4ORF4 Region
Application: 15/303,505 →
Publication: US US20170035818A1
Oncolytic Adenovirus Encoding a B7 Protein
Application: 15/570,100 →
Publication: US US20180140649A1
Oncolytic Adenovirus Encoding a B7 Protein or Active Fragment
Application: 15/231,422 →
Publication: US US20170056458A1
Oncolytic Adenovirus Encoding a B7 Protein or Active Fragment
Application: 16/134,704 →
Publication: US US20190076493A1
Oncolytic Adenovirus Encoding a Therapeutic Protein or Active Fragment
Application: 15/586,091 →
Publication: US US20170266243A1
Oncolytic Adenovirus Encoding a B7 Protein
Application: 15/799,644 →
Publication: US US20180042973A1
Virus Encoding an Anti-Tcr-Complex Antibody or Fragment
Application: 16/062,024 →
Publication: US US20180369304A1
Oncolytic Group B Adenovirus Expressing a Stroma-Targeted Bispecific T-Cell Engager
Application: 16/329,098 →
Publication: US US20190194690A1
Adenovirus Armed with Bispecific T Cell Activator
Application: 18/744,059 →
Publication: US US20250026851A1
Adenovirus Armed with Bispecific T Cell Engager
Application: 16/329,125 →
Publication: US US20190233536A1
Group B Adenovirus Encoding an Anti-Tcr-Complex Antibody or Fragment
Application: 16/062,036 →
Publication: US US20190077865A1
Group B Adenovirus Encoding an Anti-Tcr-Complex Antibody or Fragment
Application: 18/520,030 →
Publication: US US20240247061A1
Oncolytic Virus and Method
Application: 16/618,068 →
Publication: US US20200140563A1
Group B Adenovirus-Containing Formulation
Application: 16/965,549 →
Publication: US US20210121512A1
Group B Adenovirus-Containing Formulation
Application: 18/639,598 →
Publication: US US20240398879A1
Method of Purifying a Composition Comprising a Group B Adenovirus
Application: 17/596,717 →
Publication: US US20220340885A1
Adenovirus Armed with Bispecific T Cell Activator
Application: 16/641,696 →
Publication: US US20200216859A1
Adenovirus armed with bispecific T cell activator
Application: 18/481,833 →
Publication: US US20240175052A1
Adenovirus Encoding Il-15
Application: 18/546,357 →
Publication: US US20240180983A1
Virus Encoding Transgenes to Complement Cellular Therapy
Application: 19/035,441 →
Publication: US US20250269012A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 18, 2005
From: HARDEN, PAUL; HEMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSHAFT
Reel/Frame 016419/0305 →
Change of Name Aug 20, 2008
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 021411/0374 →
Assignment of Assignor's Interest Feb 18, 2011
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LTD.
Reel/Frame 025830/0722 →
Assignment of Assignor's Interest May 18, 2011
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 026298/0762 →
Assignment of Assignor's Interest Jul 26, 2012
From: HARDEN, PAUL; HERMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 028641/0336 →
Assignment of Assignor's Interest Jul 26, 2012
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 028643/0894 →
Assignment of Assignor's Interest Jul 26, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LIMITED
Reel/Frame 028641/0858 →
Change of Name Jul 26, 2012
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 028641/0806 →
Assignment of Assignor's Interest Mar 15, 2013
From: HARDEN, PAUL; HERMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 030009/0275 →
Assignment of Assignor's Interest Mar 15, 2013
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 030018/0907 →
Change of Name Mar 15, 2013
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030018/0837 →
Assignment of Assignor's Interest Mar 15, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LIMITED
Reel/Frame 030018/0193 →
Assignment of Assignor's Interest Apr 17, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LIMITED
Reel/Frame 030230/0777 →
Change of Name Apr 17, 2013
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030230/0836 →
Assignment of Assignor's Interest Apr 17, 2013
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 030230/0819 →
Assignment of Assignor's Interest Apr 17, 2013
From: HARDEN, PAUL; HERMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 030230/0685 →
Assignment of Assignor's Interest Aug 20, 2014
From: HARDEN, PAUL; HERMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 033575/0141 →
Assignment of Assignor's Interest Aug 20, 2014
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LIMITED
Reel/Frame 033575/0197 →
Change of Name Aug 20, 2014
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033577/0600 →
Assignment of Assignor's Interest Aug 21, 2014
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 033578/0751 →
Assignment of Assignor's Interest Apr 6, 2016
From: BEADLE, JOHN WILLIAM; FISHER, KERRY; WILKINSON BLANC, CHRISTINE
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 038209/0597 →
Assignment of Assignor's Interest Jul 20, 2016
From: CHAMPION, BRIAN ROBERT; BROWN, ALICE CLAIRE NOEL; FISHER, KERRY DAVID; NICOLSON, TAMARA
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 039203/0609 →
Assignment of Assignor's Interest Aug 15, 2016
From: HARDEN, PAUL; HERMISTON, TERRY; KUHN, IRENE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 039436/0161 →
Change of Name Aug 15, 2016
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 039685/0966 →
Assignment of Assignor's Interest Oct 17, 2016
From: CHAMPION, BRIAN ROBERT; BROWN, ALICE CLAIRE NOEL
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 040035/0088 →